Share This
Denosumab
Denosumab, formerly known as AMG 162, trade name Prolia, is a fully-human monoclonal antibody which is being studied in the treatment of osteoporosis, treatment induced bone loss, bone metastases, rheumatoid arthritis, multiple myeloma and giant cell tumor of bone. It is being developed by the...
Learn more about Denosumab »
Add More Topics
Save this view to a base, or just for yourself.
8 Indication topics matching:
Filter this Collection
Bone Metastases
Phase of development:
Bone Damage from Cancer
Phase of development:
Postmenopausal osteoporosis
Postmenopausal osteoporosis is a form of osteoporosis that commonly occurs during the decades after menopause. It is a pathological condition of the human skeleton that is characterized by the following features :
Osteoporosis is assessed,...
Phase of development:
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that may affect many tissues and organs, but principally attacks the joints producing an inflammatory synovitis that often progresses to destruction of the articular cartilage...
Phase of development:
Multiple myeloma
Multiple myeloma (from myelo-, bone marrow), also known as MM, myeloma, plasma cell myeloma, or as Kahler's disease (after Otto Kahler) is a cancer of the white blood cells known as plasma cells. A type of B cell, plasma cells are a crucial part of...
Phase of development:
Chronic renal failure
Chronic kidney disease (CKD), also known as chronic renal disease, is a progressive loss of renal function over a period of months or years. The symptoms of worsening kidney function are unspecific, and might include feeling generally unwell and...
Phase of development:
Anemia
Anemia (pronounced /əˈniːmiə/, also spelled anaemia and anæmia; from Ancient Greek ἀναιμία anaimia, meaning "lack of blood") is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood....
Phase of development:
